| Private Placement / Financing Transactions
City Therapeutics: The company raised $135 million of Series A venture funding in a deal led by ARCH Venture Partners on October 8, 2024. Regeneron Ventures, The Invus Group, AN Ventures, Slate Path Capital, Rock Springs Capital, Fidelity Management & Research and other undisclosed investors also participated in the round. The company is an operator of a biotechnology company intended to develop innovative, precise, and effective treatments for a wide range of diseases.
CytoVale: The company raised $100 million of Series D venture funding in a deal led by Sands Capital on October 10, 2024. Breakout Ventures, Norwest Venture Partners, Global Health Investment Corporation, and CPP Investments also participated in the round. The company is a developer of biophysical markers intended to revolutionize diagnostics using cell mechanics and machine learning.
Suki: The company raised $70 million of Series D venture funding in a deal led by Hedosophia on October 10, 2024, putting the company’s pre-money valuation at $430 million. Venrock, Flare Capital Partners, Breyer Capital, InHealth Ventures and March Capital also participated in the round. The company is a developer of a medical voice assistant intended to streamline the process of clinical documentation and reduce the administrative burden on healthcare providers.
GI Windows: The company raised $34 million in Series B venture funding from undisclosed investors on October 9, 2024, putting the company’s pre-money valuation at $96.9 million. The company is a developer of surgical devices designed to help in tissue fusion.
SynDevRx: The company raised $29.4 million of venture funding from undisclosed investors on October 10, 2024. The company is a developer of cancer therapy technology designed to treat tumors sensitive to systemic, dysregulated metabolic hormones.
Lymphatica Medtech: The company raised EUR 18 million of Series B venture funding in a deal led by Panakes Partners, Techwald Holding and CDP Venture Capital on October 8, 2024. High-Tech Gründerfonds, Occident Group, Club degli investitori, and Zürcher Kantonalbank also participated in the round. The company is a developer of implantable devices designed to re-establish lymphatic circulation in individuals affected by lymphedema.
Centaur Labs: The company raised $16 million of Series B venture funding in a deal led by Susa Ventures and SignalFire on October 8, 2024. Matrix, SBXi, Alumni Ventures, Samsung NEXT Ventures, Accel and Y Combinator also participated in the round. The company is a provider of medical data annotation services intended to offer assistance with medical decisions and diagnosis.
Spry Therapeutics: The company raised $15 million of venture funding in a deal led by Flourish Ventures on October 9, 2024. Eight Roads, F-Prime Capital and Together Fund also participated in the round. The company is a developer of a digital health platform designed for health professionals to capture and assess patient care data in real time.
Somagenetix: The company raised CHF 10 million of Series A venture funding in a deal led by VI Partners on October 8, 2024. Schroders Capital, Verve Ventures and Zürcher Kantonalbank also participated in the round. The company is an operator of a biotechnology business intended to develop new cell and gene therapy to treat patients with severe inherited immune diseases.
AltraTech: The company raised EUR 10.5 million of venture funding from EIC Scaling Club on October 7, 2024. The company is a developer of a viral deoxyribonucleic acid or ribonucleic acid detection (RNA) device designed to enhance molecular detection.
RadiantGraph: The company raised $11 million of Series A-1 venture funding in a deal led by M13 on October 9, 2024, putting the company’s pre-money valuation at $45 million. True Ventures, XYZ Venture Capital, and other undisclosed investors also participated in the round. The company is an operator of an AI-based healthcare platform intended to make healthcare more accessible and easier.
MiLaboratories: The company raised $10 million through a combination of Debt and Series A venture funding in a deal led by KFund on October 10, 2024, putting the company’s pre-money valuation at $29.5 million. EGB Capital, Courtyard Ventures, Acrobator Ventures, Speedinvest, TEN13, Somersault Ventures, and other undisclosed investors also participated in the round. The company is a developer of medical imaging software designed to provide interactive analysis of T-cell and B-cell receptor repertoire high-throughput sequencing data.
Nymbl Systems: The company raised $7.5 million of venture funding from undisclosed investors on October 11, 2024. The company is a developer of an electronic health records and practice management platform designed to improve productivity, proficiency, and profits for orthotic and prosthetic providers.
Invectys: The company raised $4 million of venture funding in the form of convertible promissory notes and warrants from undisclosed investors on October 10, 2024. The company is an operator of a biopharmaceutical business intended to develop immunotherapy products to treat cancer.
Novian Health: The company raised $3.8 million of venture funding in the form of convertible notes from undisclosed investors on October 10, 2024. The company is an operator of a proprietary medical technology platform intended to help in the treatment of tumors for early-stage breast cancer using interstitial laser therapy.
Entheos Labs: The company raised $3.6 million of venture funding from undisclosed investors on October 10, 2024. The company is a developer of bioengineering novel psychedelic botanicals designed to address unmet mental health needs.
a:head Bio: The company raised venture funding on October 9, 2024. The company is a developer of novel drugs intended for treating brain disorders based on human cerebral organoids.
Ubie: The company raised an undisclosed amount of venture funding from Alphabet on October 8, 2024. The company is a developer of a global health-tech platform intended to provide artificial intelligence (AI) disease prediction for consumers, SaaS products for healthcare providers, and marketing services for pharmaceutical organizations.
Vizgen: The company raised an undisclosed amount of Series D venture funding from Northpond Ventures, ARCH Venture Partners and Tao Capital Partners on October 9, 2024. The company is a developer of biomolecule profiling technology designed to bring new insight into biological systems and disease.
|
